Immunogenicity of a live-attenuated human rotavirus RIX4414 vaccine with or without buffering agent

Human Vaccines

Volumn 6, Issue 3, 2010, Pages 254-262

  Kerdpanich, Angkool ^a   Chokephaibulkit, Kulkanya ^b   Watanaveeradej, Veerachai ^a   Vanprapar, Nirun ^b   Simasathien, Sriluck ^a   Phavichitr, Nopaorn ^a   Bock, Hans L ^c   Damaso, Silvia ^c   Hutagalung, Yanee ^c   Han, Htay Htay ^c  

^a PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Buffer; Immunogenicity; Infants 6 12 weeks; Rotavirus; Thailand

Indexed keywords

BUFFER; CALCIUM CARBONATE; IMMUNOGLOBULIN A; PLACEBO; ROTAVIRUS VACCINE; WATER;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG SAFETY; FEEDING BEHAVIOR; FOLLOW UP; GASTROENTERITIS; GENE SEQUENCE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFANT; NORMAL HUMAN; SEROCONVERSION; VACCINATION;

EID: 77953647117     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.3.10428     Document Type: Article

References (26)

1. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565-72.
2. Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006; 12:304-6.
3. Santosham M, Nelson EAS, Bresee JS. Implementing rotavirus vaccination in Asia. Vaccine 2007; 25:7711-6.
4. Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD. Rotavirus vaccines: targeting the developing world. J Infect Dis 2005; 192:160-6.
5. Grimwood K, Buttery JP. Clinical update: rotavirus gastroenteritis and its prevention. Lancet 2007; 370:302-4.
6. Bresee JS, Hummelman E, Nelson EAS, Glass RI. Rotavirus in Asia: The value of surveillance for informing decisions about the introduction of new vaccines. J Infect Dis 2005; 192:1-5.
7. Maneekarn N, Ushijima H. Epidemiology of rotavirus infection in Thailand. Pediatr Int 2000; 42:415-21.
8. Jiraphongsa C, Bresee JS, Pongsuwanna Y, Kluabwang P, Poonawagul U, Arporntip P, et al. Epidemiology and burden of rotavirus diarrhea in Thailand: Results of Sentinel Surveillance. J Infect Dis 2005; 192:87-93.
9. Bresee J, Fang ZY, Wang B, Nelson EAS, Tam J, Soenarto Y, et al. First Report from the Asian Rotavirus Surveillance Network. Emerg Infect Dis 2004; 10:988-95.
10. Araujo EC, Clemens SAC, Oliveira CS, Justino MCA, Rubio P, Gabbay YB, et al. Safety, immunogenicity and protective efficacy of two doses of RIX4414 live-attenuated human rotavirus vaccine in healthy Brazilian infants. J Pediatr (Rio J) 2007; 83:217-24.
11. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22.
12. Glass RI, Parashar UD, Bresee JS, Turcios R, Fischer TK, Widdowson MA, et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006; 368:323-32.
13. Linhares AC, Velázquez FR, Schael IP, Llorens XS, Abate H, Espinoza F, et al. Efficacy and safety of an oral live-attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomized, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1181-9.
14. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomized, double-blind controlled study. Lancet 2007; 370:1757-63.
15. th International Congress on Infectious Diseases (ICID); 2008; Kuala Lumpur, Malaysia.
16. Glass RI, Parashar UD, Bresee JS, Turcios R, Fischer TK, Widdowson MA, et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006; 368:323-32.
17. Linhares AC, Ruiz-Palacios GM, Guerrero ML, Salinas B, Perez-Schael I, Clemens SAC, et al. A short report on highlights of world-wide development of RIX4414: A Latin American experience. Vaccine 2006; 24:3784-5.
18. Ing DJ, Glass RI, Woods PA, Simonetti M, Pallansch MA, Wilcox WD, et al. Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral rotavirus vaccine. Am J Dis Child 1991; 145:802-7.
19. Pichichero ME, Marsocci SM, Francis AB, Green JL, Disney FA, Rennels MB, et al. A comparative evaluation of the safety and immunogenicity of a single dose of unbuffered oral rhesus rotavirus serotype 3, rhesus/human reassortant serotypes 1, 2 and 4 and combined (tetravalent) vaccines in healthy infants. Vaccine 1993; 11:747-53.
20. 2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatr Infect Dis J 2003; 22:914-20.
21. Weiss C, Clark HF. Rapid inactivation of rotaviruses by exposure to acid buffer or acidic gastric juice. J gen Viro 1985; 66:2725-30. (Pubitemid 16180034)
22. Schulz KF, Grimes DA. Multiplicity in randomized trials II: subgroup and interim analyses. Lancet 2005; 365:1657-61.
23. Rennels MB. Influence of breast feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. J Infect Dis 1996; 174:107-11.
24. Bernstein DI, Smith VE, Sherwood JR, Schiff GM, Sander DS, DeFeudist D, et al. Safety and immunogenicity of a live-attenuated human rotavirus 89-12 vaccine. Vaccine 1998; 16:381-7.
25. Bernstein DI, Sack DA, Rothstein E, Reisinger K, Smith VE, O'Sullivan D, et al. Efficacy of live-attenuated human rotavirus vaccine 89-12 in infants. Lancet 1999; 354:287-90.
26. Pang XL, Joensuu J, Hoshino Y, Kapikian AZ, Vesikari T. Rotaviruses detected by reverse transcription polymerase chain reaction in acute gastroenteritis during a trial of rhesus-human reassortant rotavirus tetravalent vaccine: implications for vaccine efficacy analysis. J Clin Virol 1999; 13:9-16.